List of Excipients in Branded Drug NIZATIDINE

Generic Drugs Containing NIZATIDINE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	nizatidine	0591-3137	AMMONIA
Actavis Pharma Inc	nizatidine	0591-3137	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	nizatidine	0591-3137	D&C YELLOW NO. 10
Actavis Pharma Inc	nizatidine	0591-3137	FD&C YELLOW NO. 6
Actavis Pharma Inc	nizatidine	0591-3137	FERROSOFERRIC OXIDE
Actavis Pharma Inc	nizatidine	0591-3137	GELATIN
Actavis Pharma Inc	nizatidine	0591-3137	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in NIZATIDINE?

# Of NDCs	Excipient
3	ALCOHOL
9	AMMONIA
1	ANHYDROUS CITRIC ACID
3	BUTYL ALCOHOL
1	COLLOIDAL SILICON DIOXIDE
11	CROSCARMELLOSE SODIUM
1	D&C RED NO. 28

Nizatidine Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Nizatidine is an off-patent H2-receptor antagonist with established oral capsule and oral-solution dosage forms. Its commercial opportunity is not based on molecule exclusivity. It lies in differentiated excipient systems, nitrosamine-controlled manufacturing, pediatric and geriatric delivery, taste masking, improved moisture protection, and regional generic supply.

The highest-value development path is a stable, low-cost oral solid dosage form supported by a strong nitrosamine-control package. Liquid and orally disintegrating products offer higher differentiation but face greater formulation, stability, taste, and regulatory risks.

What is nizatidine and how is it currently used?

Nizatidine is an H2-receptor antagonist indicated for duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease. It reduces gastric acid secretion by blocking histamine H2 receptors on gastric parietal cells.

Attribute	Nizatidine
Active ingredient	Nizatidine
Drug class	Histamine H2-receptor antagonist
Common strengths	150 mg and 300 mg capsules
Oral liquid strength	15 mg/mL in historical and generic products
Route	Oral
Key indications	GERD, duodenal ulcer, gastric ulcer
Reference product	Axid
Innovator	Eli Lilly
Regulatory status	Generic prescription product in the United States
Biosimilar relevance	None; nizatidine is a small molecule
Main commercial concern	Nitrosamine contamination and declining demand for older acid-suppression products

The FDA-approved labeling identifies nizatidine capsules and oral solution as immediate-release products. The drug is generally administered once or twice daily, depending on indication and patient characteristics (U.S. Food and Drug Administration [FDA], 2018).

What excipients are used in nizatidine capsules and oral solution?

Nizatidine formulations typically use conventional immediate-release excipients. Exact compositions vary by manufacturer and market.

Capsule excipients

Commercial nizatidine capsules may contain:

• Microcrystalline cellulose as a diluent and compression aid
• Pregelatinized starch or other starch derivatives as a binder and disintegrant
• Crospovidone or croscarmellose sodium as a superdisintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Gelatin for the capsule shell
• Titanium dioxide and approved colorants
• Printing inks containing pharmaceutical pigments and solvents

The primary formulation challenge is achieving rapid dissolution without increasing moisture exposure. Nizatidine is a highly water-soluble active ingredient, so excessive reliance on highly porous excipients may increase water uptake during storage.

Oral-solution excipients

Nizatidine oral solution products may use:

• Purified water
• Sweeteners such as sucrose, sorbitol, or sucralose
• Preservatives such as sodium benzoate or parabens
• Buffering agents
• Flavoring agents
• Chelating agents
• Viscosity modifiers
• Colorants

Liquid products require closer control of pH, microbial quality, preservative effectiveness, extractables, leachables, and flavor stability than capsules. The active ingredient's sulfur-containing structure also makes impurity and oxidation control relevant during development.

What excipient strategy is best for a nizatidine generic?

The optimal baseline strategy is a low-moisture, immediate-release capsule or tablet using standard compendial excipients and a protective package.

A practical formulation platform would include:

Formulation objective	Preferred excipient approach	Commercial rationale
Rapid release	Microcrystalline cellulose with crospovidone or croscarmellose sodium	Supports simple bioequivalence development
Low moisture uptake	Anhydrous diluents and low-hygroscopic disintegrants	Improves stability and reduces impurity growth
Manufacturing flow	Colloidal silicon dioxide	Supports high-speed encapsulation or compression
Lubrication	Low-level magnesium stearate or sodium stearyl fumarate	Limits dissolution impact
Taste control	Film coating or capsule presentation	Avoids direct exposure of the active ingredient
Oxidation control	Low-oxygen packaging and controlled processing	Supports impurity control without unnecessary additives
Patient convenience	Unit-dose blister or bottle with desiccant	Reduces moisture and handling risk

A capsule remains the lowest-risk product because it avoids the taste, preservative, and microbial challenges associated with oral liquids. A tablet can reduce manufacturing cost, but its commercial advantage depends on scale and target markets.

What nizatidine formulations offer the strongest commercial opportunity?

1. Nitrosamine-controlled capsules

The most immediate opportunity is a reliable generic capsule supported by documented control of N-nitrosodimethylamine, or NDMA.

Nizatidine products were affected by nitrosamine concerns after NDMA was detected in some products. The FDA identified the possibility that NDMA could form during manufacture or storage, particularly under conditions involving susceptible impurities, elevated temperature, and prolonged storage (FDA, 2020a; FDA, 2020b).

A sponsor can differentiate through:

• Low-nitrite excipient sourcing
• Supplier qualification for nitrite and nitrate content
• Control of dimethylamine-related impurities
• Defined manufacturing temperature and hold-time limits
• Oxygen and moisture control
• Stability testing under accelerated and long-term conditions
• Validated NDMA analytical methods
• Container-closure studies
• Periodic risk-based nitrosamine testing

This strategy can support supply agreements with wholesalers, hospital systems, and pharmacy chains that prioritize continuity of supply.

2. Pediatric oral solution

Nizatidine oral solution can address patients who cannot swallow capsules. The main formulation barriers are bitterness, chemical stability, microbial preservation, and dosing accuracy.

A differentiated liquid could use:

• A multi-component taste-masking system
• Low-sugar or sugar-free sweetening
• A pH range that balances stability and palatability
• A preservative system validated under USP <51>
• A calibrated oral syringe
• A child-resistant, senior-friendly closure
• Packaging that limits oxygen and moisture ingress

Sorbitol-based or sugar-free systems may support diabetic and pediatric positioning, but they can create gastrointestinal tolerability issues at higher doses. Sucrose improves palatability but increases dental and labeling concerns.

3. Orally disintegrating tablets

An orally disintegrating nizatidine tablet could target older adults, dysphagia patients, and outpatient settings. The product would require robust taste masking because rapid disintegration exposes the active ingredient in the mouth.

Potential excipient systems include:

• Mannitol for mouthfeel and cooling sensation
• Crospovidone for rapid disintegration
• Copovidone or hydroxypropyl cellulose for granule binding
• Coated drug particles for taste masking
• Low levels of sweeteners and flavors
• Moisture-barrier blister packaging

This product has greater differentiation than a conventional capsule but faces higher development risk. Taste masking must remain effective after storage, and the product must meet rapid-disintegration and dissolution requirements.

4. Multiparticulate products

Sprinkle capsules or sachets containing coated pellets could serve patients with swallowing difficulty. Multiparticulates permit dose flexibility and can be mixed with soft food, but they increase manufacturing complexity.

The commercial case is stronger in pediatric or geriatric markets than in the broad adult generic market. The sponsor would need to establish uniformity after sprinkling, compatibility with food, pellet integrity, and stability after opening.

When did nizatidine lose exclusivity?

Nizatidine's original U.S. exclusivity and patent protection have expired. Generic competition has existed for many years, and the product does not have the commercial profile of a currently protected small molecule.

The reference product, Axid, was approved in the late 1980s. FDA records identify nizatidine as an established product with approved generic alternatives rather than a product protected by current new chemical entity exclusivity (FDA, 2018).

Exclusivity category	Current position
New chemical entity exclusivity	Expired
Original composition patents	Expired
Pediatric exclusivity	No current market significance
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Formulation exclusivity	No broad current barrier apparent
Generic competition	Established

A current developer should focus on regulatory execution, supply reliability, formulation differentiation, and procurement access rather than molecule-level patent protection.

What patents protect nizatidine products today?

The original nizatidine patent estate is historical. Broad active-ingredient protection has expired, and commercial products are generally exposed to generic competition.

Current protection may still arise from:

• Newly developed taste-masking systems
• Specialized liquid formulations
• Novel multiparticulate coatings
• Packaging configurations
• Manufacturing processes
• Stability-improving excipient combinations
• Combination products
• Method-of-use claims in jurisdictions where such claims remain enforceable

These rights would protect a particular implementation, not nizatidine itself. A sponsor seeking patent value should claim measurable technical effects, such as reduced NDMA formation, extended shelf life, improved palatability, or improved dose uniformity.

A formulation patent is more defensible when it identifies a narrow excipient ratio, defined pH range, impurity limit, process condition, and stability result. A broad claim covering nizatidine with routine excipients would face substantial validity and obviousness risk.

What is the Orange Book status of nizatidine?

The Orange Book has historically listed Axid and approved nizatidine products. The relevant regulatory framework is abbreviated new drug application approval under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

For a current product launch, the critical Orange Book issues are:

• Whether the reference listed drug remains listed
• Whether the intended dosage form and strength have an approved reference product
• Whether any listed patents or regulatory exclusivities remain active
• Whether a Paragraph IV certification is required
• Whether the proposed formulation is therapeutically equivalent to the reference product

Because nizatidine is an old genericized product, the principal regulatory work is likely to involve bioequivalence, manufacturing controls, stability, labeling, and nitrosamine risk management rather than a complex patent certification strategy.

Are Paragraph IV challenges relevant to nizatidine?

Paragraph IV litigation risk is limited for the original nizatidine molecule because the principal patent estate has expired. A Paragraph IV filing could still arise if a new formulation or method patent is listed for a differentiated product.

The practical risk profile is:

Scenario	Paragraph IV exposure
Conventional 150 mg capsule	Low
Conventional 300 mg capsule	Low
Standard oral solution	Low to moderate, depending on listed patents
Taste-masked orally disintegrating tablet	Potentially material if patented
Novel multiparticulate product	Potentially material
NDMA-control manufacturing process	Possible, but difficult to enforce broadly
New combination product	Depends on listed patents and regulatory exclusivity

A sponsor should not assume that a new formulation creates meaningful market exclusivity. The patent must be listed, technically defensible, and commercially relevant to the product that competitors seek to copy.

What regulatory risks affect nizatidine development?

Nitrosamine risk

NDMA is the central regulatory issue. FDA guidance requires manufacturers to evaluate nitrosamine risks across active ingredients, excipients, water, processing conditions, packaging, and storage.

Risk controls should include:

1. Supplier testing for nitrite and nitrate impurities.
2. Assessment of dimethylamine and related amine precursors.
3. Evaluation of pH and temperature effects.
4. Testing at release and throughout shelf life.
5. Separate control strategies for API and finished product.
6. Defined acceptance criteria based on applicable FDA limits.

A product with strong release testing but weak stability data may still face regulatory intervention.

Excipient supply risk

Excipient suppliers can affect both quality and patent position. A change in starch, cellulose, lubricant, flavor, or preservative can alter dissolution, impurity formation, and bioequivalence.

The development package should therefore define:

• Excipient grade
• Particle-size distribution
• Water content
• Nitrite and nitrate limits
• Peroxide values where relevant
• Supplier change-control requirements
• Acceptable substitution ranges

Oral-solution risk

Liquid products require validated microbial controls and preservative effectiveness. The sponsor must also manage dose measurement, in-use stability, container compatibility, and flavor consistency.

How does nizatidine compare with famotidine and other acid reducers?

Nizatidine competes with famotidine, proton-pump inhibitors, antacids, and over-the-counter acid reducers.

Product	Class	Market position	Formulation opportunity
Nizatidine	H2 antagonist	Mature generic	Low-cost capsule, liquid, ODT
Famotidine	H2 antagonist	Stronger current recognition	Chewable, OTC, combination formats
Cimetidine	H2 antagonist	Older product with interaction concerns	Limited
Omeprazole	Proton-pump inhibitor	Broad OTC and prescription use	Delayed-release systems
Pantoprazole	Proton-pump inhibitor	Prescription and generic	Delayed-release tablets
Calcium carbonate products	Antacid	OTC, rapid symptom relief	Chewable and effervescent forms

Famotidine has a stronger commercial position in many markets because of brand recognition and broad OTC availability. Nizatidine can compete where supply reliability, price, pediatric dosing, or a differentiated formulation matters.

Which companies are challenging or supplying nizatidine?

Nizatidine has been supplied by multiple generic manufacturers and contract manufacturers over time. The competitive field is fragmented and may vary by country, product strength, dosage form, and current marketing status.

The commercial competition is primarily between:

• Established generic pharmaceutical companies
• Regional manufacturers
• Contract development and manufacturing organizations
• Private-label suppliers
• Hospital and institutional suppliers

Because the molecule is mature, the winning advantage is usually manufacturing economics, regulatory reliability, and distribution rather than clinical differentiation.

What licensing deals and manufacturing barriers matter?

Large licensing transactions are unlikely for a conventional nizatidine capsule. More relevant opportunities include:

• Regional marketing partnerships
• Private-label supply agreements
• Contract manufacturing
• Pediatric formulation licensing
• Taste-masking technology licenses
• Nitrosamine-control technology
• Hospital procurement contracts

Manufacturing barriers include low-volume economics, API availability, analytical testing costs, liquid-product complexity, and the need to maintain consistent excipient sourcing.

A developer can improve margins by using the same platform for 150 mg and 300 mg strengths, minimizing granulation steps, and selecting a package that supports a longer shelf life without excessive material cost.

What generic launch scenarios exist for nizatidine?

Low-cost capsule launch

This is the fastest and lowest-risk path. It requires standard immediate-release performance, established excipients, competitive API sourcing, and a credible nitrosamine-control program.

Premium liquid launch

This approach targets pediatric, geriatric, and institutional use. It supports higher unit pricing but requires stronger taste, stability, and microbiological data.

Differentiated ODT launch

This product can create a defensible formulation position but requires taste masking, specialized equipment, and potentially greater packaging cost.

Regional supply launch

A manufacturer can target markets where nizatidine remains listed, where famotidine access is limited, or where hospital formularies favor low-cost H2 antagonists.

What is the revenue exposure for a nizatidine product?

Revenue potential is constrained by low generic pricing and the availability of substitutes. A conventional capsule typically has limited pricing power. A differentiated liquid or ODT may support higher gross margins but will address a smaller market.

The most attractive revenue channels are:

• Institutional supply contracts
• Pediatric and geriatric products
• Markets with limited H2-antagonist availability
• Private-label pharmacy products
• Regional tenders
• Reliable supply during competitor shortages

A sponsor should model revenue by dosage form and channel rather than by total H2-antagonist demand. Nizatidine's product-level sales are likely to remain modest unless the manufacturer secures a supply disruption advantage or launches a differentiated dosage form.

Key Takeaways

• Nizatidine is an off-patent, genericized H2-receptor antagonist.
• Conventional capsules offer the lowest development and regulatory risk.
• Nitrosamine control is the most important technical and commercial differentiator.
• Oral solutions create pediatric and geriatric opportunities but require taste, preservative, microbial, and stability controls.
• Orally disintegrating and multiparticulate products offer stronger differentiation but higher development costs.
• Broad molecule-level patent protection is no longer commercially relevant.
• New formulation patents must rely on narrow, technically supported claims.
• The principal competitive advantages are reliable supply, low impurity levels, stable packaging, and targeted dosage forms.
• Biosimilar risk does not apply because nizatidine is a small molecule.
• Paragraph IV risk is low for standard products and higher only where a new formulation or method patent is listed.

FAQs

Is nizatidine still commercially viable?

Yes, but mainly as a low-cost generic or differentiated formulation. The strongest opportunities are nitrosamine-controlled capsules, pediatric liquids, and taste-masked orally disintegrating products.

Which excipient is best for improving nizatidine stability?

No single excipient determines stability. Low-moisture excipient grades, controlled nitrite content, protective packaging, and validated storage conditions are more important than selecting one proprietary excipient.

Can an nizatidine oral solution receive new patent protection?

Yes. Protection may be available for a specific taste-masking system, preservative combination, pH range, stability profile, or packaging configuration. The claims must be narrower than the expired compound claims.

Does nizatidine have biosimilar competition?

No. Biosimilars apply to biological products. Nizatidine is a chemically synthesized small molecule and competes through abbreviated generic applications.

What is the main reason to choose nizatidine over famotidine?

Nizatidine may be selected for supply availability, price, existing product registrations, pediatric or liquid dosage-form requirements, or a specific formulary strategy. Famotidine generally has stronger market recognition.

References

1. U.S. Food and Drug Administration. (2018). Nizatidine prescribing information. FDA.

2. U.S. Food and Drug Administration. (2020a). FDA updates on nitrosamine in ranitidine and nizatidine medicines. FDA.

3. U.S. Food and Drug Administration. (2020b). Control of nitrosamine impurities in human drugs: Guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary. USP.